Bedaquiline, pretomanid, linezolid,  and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis:  a systematic review

Silva1, Denise Rossato; Fernandes2, Flávia Fonseca; Ferreira3, Juliana Carvalho; Bernando4, Wanderley; Dalcolmo5, Margareth Maria Pretti; Johansen6, Fernanda Dockhorn Costa; Mello7, Fernanda Carvalho de Queiroz

138
Views

Back to summary

Open Access

Peer-Reviewed
Meta-análise

Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review

Denise Rossato Silva1, Flávia Fonseca Fernandes2, Juliana Carvalho Ferreira3, Wanderley Bernando4, Margareth Maria Pretti Dalcolmo5, Fernanda Dockhorn Costa Johansen6, Fernanda Carvalho de Queiroz Mello7

How to cite this article

Silva1 DR, Fernandes2 FF, Ferreira3 JC, Bernando4 W, Dalcolmo5 MMP, Johansen6 FDC, et al. Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review. J Bras Pneumol. 2024;50(6):e20240295